Company: RGNT
Filing Date: 2025-01-27
Form Type: DRS/A
Source: 0001213900-25-006676
Chunk: 154

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-01-27
Form: DRS/A
Chunk 154
---
 listing of our securities
on the Nasdaq Capital Market, with each executive officer and director pursuant to which we will indemnify each of them up to a certain
amount and to the extent that these liabilities are not covered by directors and officers’ insurance.

We
have also entered into a Chief Financial Officer Services Agreement, or the CFO Services Agreement, dated December 5, 2022, with
Shimony, pursuant to which the Company retains CFO services from Shimony that are provided by Mr. Arie Gordashnikov. Mr.
Gordashnikov, who has been employed by the Company since October 1, 2022, serves as the Chief Financial Officer of the Company and
devotes all of the time and effort required for our business and activities on a full-time basis. Pursuant to the CFO Services
Agreement, Mr. Gordashnikov is expected to continue to serve as our CFO following the completion of this offering, and the Company will pay Shimony $3,000 per month plus Value-Added Tax for Mr. Gordashnikov’s services from such time as the Company completes an IPO. The CFO Services Agreement may be terminated by either the Company or Shimony upon 60 days’ prior written notice. The CFO Services Agreement further provides that Mr. Gordashnikov shall not provide CFO services to any third party and shall not engage in any other employment, consulting or other business activity (whether full-time or part-time) that would create a conflict of interest with the Company. The CFO Services Agreement also includes standard non-compete, non-solicitation and confidentiality provisions. In addition, Mr. Gordashnikov will enter into a standard indemnification agreement with the Company.

<div align='center'>93</div>

For
a description of the terms of our options and option plans, see “Management—Equity Incentive Plan”below.

Directors’ Service Contracts

Other than with respect to
our directors that are also executive officers, we do not have written agreements with any director providing for benefits upon the termination
of his employment with our company.

Differences between the Companies Law and Nasdaq Requirements

The Sarbanes-Oxley Act, as
well as related rules subsequently implemented by the SEC, require foreign private issuers, such as us, to comply with various corporate
governance practices. In addition, following the listing of the Ordinary Shares on Nasdaq, we will be required to comply with the Nasdaq
Stock Market rules. Under